# US 2024/0197913 A1 · Compositions and methods for treating retinal degenerative disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197913 A1
- Document ID: US20240197913A1
- Status: Published application
- Kind: A1
- Application number: 18/287,758
- Filed: 2022-04-20
- Published: 2024-06-20
- Earliest claimed: 2021-04-20
- Assignees: Inserm (Institut National De La Sante Et De La Recherche Medicale); Sparingvision; Centre National De La Recherche Scienfitique - Crns -; Sorbonne Universite
- Applicants: Inserm (Institut National De La Santé Et De La Recherche MéDicale); Sparingvision; Centre National De La Recherche Scienfitique - Crns -; Sorbonne Universite
- Inventors: Deniz DALKARA; Hanen KHABOU; Florence LORGET; José SAHEL; Simon CARDILLA-JOE
- Web page: https://patentgrep.com/patent/US20240197913A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 38/1709: {from mammals}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61P 27/02: Ophthalmic agents
- C07K 14/435: from animals; from humans
- C12N 15/85: for animal cells
- C12N 15/86: Viral vectors
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- C07K 2319/50: containing protease site
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N 2830/48: regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- C12N 2840/20: translation of more than one cistron
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to the combination of a nucleic acid encoding a short isoform of rod-derived cone viability factor (RdCVF), a nucleic acid encoding a long isoform of rod-derived cone viability factor (RdCVFL) and a nucleic acid encoding a G protein-activated Inward Rectifier potassium channel 2 (GIRK2), expressed through one, two or three viral vectors, said vectors may be within a single pharmaceutical composition or within several different pharmaceutical compositions (two or three). It also deals with the treatment of a retinal degenerative disease, in particular the retinitis pigmentosa, with said viral vectors or pharmaceutical compositions.

## Claims

### Claim 1

A pharmaceutical composition comprising one or several viral vectors, wherein said one or several viral vectors comprise a nucleic acid encoding a short isoform of rod-derived cone viability factor (RdCVF), a nucleic acid encoding a long isoform of rod-derived cone viability factor (RdCVFL) and a nucleic acid encoding a G protein-activated Inward Rectifier potassium channel 2 (GIRK2).

### Claim 2 (depends on 1)

A pharmaceutical composition according to claim 1, wherein said composition comprises a first viral vector comprising a nucleic acid encoding RdCVF and a nucleic acid encoding RdCVFL, and a second viral vector comprising a nucleic acid encoding GIRK2.

### Claim 3 (depends on 1)

A pharmaceutical composition according to claim 1, wherein said composition comprises three viral vectors respectively comprising a nucleic acid encoding RdCVF, a nucleic acid encoding RdCVFL, and a nucleic acid encoding GIRK2.

### Claim 4 (depends on 1)

A pharmaceutical composition according to claim 1, wherein said pharmaceutical composition comprises a single viral vector, said single viral vector comprising three nucleic acids respectively encoding RdCVF, RdCVFL and GIRK2.

### Claim 5

A viral vector comprising three nucleic acids respectively encoding RdCVF, RdCVFL and GIRK2.

### Claim 6

A kit comprising two pharmaceutical compositions, wherein:
the first pharmaceutical composition comprises a viral vector which comprises a nucleic acid encoding RdCVF and a nucleic acid encoding RdCVFL, and
the second pharmaceutical composition comprises a viral vector which comprises a nucleic acid encoding GIRK2.

### Claim 7

A kit comprising three pharmaceutical compositions, wherein:
the first pharmaceutical composition comprises a viral vector, said viral vector comprising a nucleic acid encoding RdCVF,
the second pharmaceutical composition comprises a viral vector, said viral vector comprising a nucleic acid encoding RdCVFL, and
the third pharmaceutical composition comprises a viral vector, said viral vector comprising a nucleic acid encoding GIRK2.

### Claim 8 (depends on 1)

A pharmaceutical composition according to claim 1, wherein said RdCVF is the human short isoform hRdCVF as set forth in SEQ ID NO:1.

### Claim 9 (depends on 1)

A pharmaceutical composition according to claim 1 wherein said RdCVFL is the human long isoform hRdCVFL as set forth in SEQ ID NO:2.

### Claim 10 (depends on 1)

A pharmaceutical composition according to claim 1 wherein said GIRK2 is the human GIRK2 sequence as forth in SEQ ID NO:9.

### Claim 11 (depends on 1)

A method of treating a retinal degenerative disease comprising providing a subject in need thereof a pharmaceutical composition according to claim 1.

### Claim 12 (depends on 11)

The method of claim 11 wherein said retinal degenerative disease is a rod-cone dystrophy, a cone dystrophy, a cone-rod dystrophy or an atrophic age-related macular degeneration.

### Claim 13 (depends on 11)

The method of claim 11 wherein said retinal degenerative disease is selected in the group consisting of retinitis pigmentosa, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-Kornzweig syndrome, Best disease, choroideremia, gyrate atrophy, Leber congenital amaurosis, Refsum disease, Stargardt disease or Usher syndrome.

### Claim 14 (depends on 11)

The method of claim 11 wherein said retinal degenerative disease is the retinitis pigmentosa.

### Claim 15 (depends on 11)

The method of claim 11 wherein providing is performed by subretinal injection, intravitreal injection or suprachoroidal injection.

### Claim 16 (depends on 5)

A viral vector according to claim 5, wherein said RdCVF is the human short isoform hRdCVF as set forth in SEQ ID NO:1.

### Claim 17 (depends on 5)

A viral vector according to claim 5, wherein said RdCVFL is the human long isoform hRdCVFL as set forth in SEQ ID NO:2.

### Claim 18 (depends on 5)

A viral vector according to claim 5, wherein said GIRK2 is the human GIRK2 sequence as forth in SEQ ID NO:9.

### Claim 19 (depends on 1)

A method of treating a retinal degenerative disease comprising providing a subject in need thereof a viral vector according to claim 1.

### Claim 20 (depends on 19)

The method according to claim 19 wherein said retinal degenerative disease is a rod-cone dystrophy, a cone dystrophy, a cone-rod dystrophy or an atrophic age-related macular degeneration.

### Claim 21 (depends on 19)

The method according to claim 19 wherein said retinal degenerative disease is selected in the group consisting of retinitis pigmentosa, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-Kornzweig syndrome, Best disease, choroideremia, gyrate atrophy, Leber congenital amaurosis, Refsum disease, Stargardt disease or Usher syndrome.

### Claim 22 (depends on 19)

The method according to claim 19 wherein said retinal degenerative disease is the retinitis pigmentosa.

### Claim 23 (depends on 19)

The method according to claim 19 wherein providing is performed by subretinal injection, intravitreal injection or suprachoroidal injection.
